After backlash, Teva to resume supplies of critical children's cancer drug

After backlash, Teva to resume supplies of critical children's cancer drug

What to read around the web today

• Meet Ryan Denu, STAT 2019 Wunderkind. STAT
• Unexpected clues emerge about why diets fail. Nature Medicine
• The influencer scientists debunking online misinformation. Wired
• The llama as therapist. The New York Times
• After backlash, Teva will resume supplies of a critical children’s cancer medicine. STAT Plus